New York State Common Retirement Fund lessened its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 20.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 118,717 shares of the company's stock after selling 30,522 shares during the quarter. New York State Common Retirement Fund owned about 0.06% of Cencora worth $26,721,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in COR. Lake Street Advisors Group LLC boosted its position in Cencora by 1.3% during the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock worth $769,000 after purchasing an additional 43 shares during the period. Financial Advocates Investment Management grew its stake in Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock valued at $220,000 after buying an additional 44 shares during the last quarter. Checchi Capital Advisers LLC raised its holdings in Cencora by 2.2% in the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock worth $499,000 after acquiring an additional 48 shares during the period. J.W. Cole Advisors Inc. raised its holdings in Cencora by 1.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company's stock worth $826,000 after acquiring an additional 48 shares during the period. Finally, Valeo Financial Advisors LLC lifted its position in Cencora by 3.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company's stock worth $353,000 after acquiring an additional 51 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.
A number of analysts have issued reports on the company. Leerink Partners lowered their target price on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Robert W. Baird reduced their price target on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a report on Friday, September 6th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a report on Wednesday, August 21st. Finally, Evercore ISI reduced their target price on shares of Cencora from $270.00 to $250.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $259.44.
Read Our Latest Report on Cencora
In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now directly owns 285,088 shares of the company's stock, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,473 shares of the business's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company's stock, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.80% of the stock is currently owned by insiders.
NYSE COR opened at $234.27 on Monday. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The company's 50-day simple moving average is $231.39 and its 200 day simple moving average is $230.60. The stock has a market cap of $46.16 billion, a P/E ratio of 25.44, a PEG ratio of 1.45 and a beta of 0.44. Cencora, Inc. has a twelve month low of $184.00 and a twelve month high of $247.66.
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.